×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
IONS – ionis pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
IONS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/30
06:01 am
ions
This 11-year-old has battled a rare disease for years — a breakthrough drug helped deliver relief [CNBC]
Low
Report
This 11-year-old has battled a rare disease for years — a breakthrough drug helped deliver relief [CNBC]
1/28
08:03 am
ions
Ionis Pharmaceuticals (NASDAQ:IONS) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $95.00 price target on the stock.
Low
Report
Ionis Pharmaceuticals (NASDAQ:IONS) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $95.00 price target on the stock.
1/24
05:09 am
ions
Ionis Pharmaceuticals (NASDAQ:IONS) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Ionis Pharmaceuticals (NASDAQ:IONS) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
1/21
07:00 am
ions
DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)
Low
Report
DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)
1/13
02:41 pm
ions
Assessing Ionis Pharmaceuticals (IONS) Valuation After A Strong 1 Year Shareholder Return [Yahoo! Finance]
Low
Report
Assessing Ionis Pharmaceuticals (IONS) Valuation After A Strong 1 Year Shareholder Return [Yahoo! Finance]
1/12
07:00 am
ions
Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts
Low
Report
Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts
1/8
06:16 am
ions
GSK, Ionis claim study success for RNA-based hepatitis B drug [Yahoo! Finance]
Medium
Report
GSK, Ionis claim study success for RNA-based hepatitis B drug [Yahoo! Finance]
1/7
03:53 am
ions
GSK Reports 'Positive' Phase 3 Results From Chronic Hepatitis B Studies [Yahoo! Finance]
Low
Report
GSK Reports 'Positive' Phase 3 Results From Chronic Hepatitis B Studies [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
10/29/2025
07:00 am
IONS
ionis pharmaceuticals, inc.
BEAT
Report
-2.9%
ionis pharmaceuticals, inc.
7/30/2025
07:00 am
IONS
ionis pharmaceuticals, inc.
BEAT
Report
4.5%
ionis pharmaceuticals, inc.
4/30/2025
07:00 am
IONS
ionis pharmaceuticals, inc.
BEAT
Report
1.4%
ionis pharmaceuticals, inc.
2/19/2025
07:00 am
IONS
ionis pharmaceuticals, inc.
BEAT
Report
-1.6%
ionis pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/4
04:07 pm
ions
Form 4 IONIS PHARMACEUTICALS For: Feb 02 Filed by: BENNETT C FRANK
Low
Report
Form 4 IONIS PHARMACEUTICALS For: Feb 02 Filed by: BENNETT C FRANK
2/2
08:52 pm
ions
Form 4 IONIS PHARMACEUTICALS For: Jan 29 Filed by: Swayze Eric
Low
Report
Form 4 IONIS PHARMACEUTICALS For: Jan 29 Filed by: Swayze Eric
2/2
08:52 pm
ions
Form 4 IONIS PHARMACEUTICALS For: Jan 29 Filed by: Monia Brett P
Low
Report
Form 4 IONIS PHARMACEUTICALS For: Jan 29 Filed by: Monia Brett P
2/2
08:52 pm
ions
Form 4 IONIS PHARMACEUTICALS For: Jan 29 Filed by: O'NEIL PATRICK R.
Low
Report
Form 4 IONIS PHARMACEUTICALS For: Jan 29 Filed by: O'NEIL PATRICK R.
2/2
08:52 pm
ions
Form 4 IONIS PHARMACEUTICALS For: Jan 29 Filed by: Schneider Eugene
Low
Report
Form 4 IONIS PHARMACEUTICALS For: Jan 29 Filed by: Schneider Eugene
2/2
08:52 pm
ions
Form 4 IONIS PHARMACEUTICALS For: Jan 29 Filed by: HOUGEN ELIZABETH L
Low
Report
Form 4 IONIS PHARMACEUTICALS For: Jan 29 Filed by: HOUGEN ELIZABETH L
2/2
08:51 pm
ions
Form 4 IONIS PHARMACEUTICALS For: Jan 29 Filed by: BENNETT C FRANK
Low
Report
Form 4 IONIS PHARMACEUTICALS For: Jan 29 Filed by: BENNETT C FRANK
2/2
08:51 pm
ions
Form 4 IONIS PHARMACEUTICALS For: Jan 29 Filed by: Baroldi Joseph
Low
Report
Form 4 IONIS PHARMACEUTICALS For: Jan 29 Filed by: Baroldi Joseph
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/23
Form 4 IONIS PHARMACEUTICALS For: Mar 19 Filed by: CROOKE STANLEY T
7.8%
3/3 Form 4 IONIS PHARMACEUTICALS For: Feb 29 Filed by: O'NEIL PATRICK R. 7.6%
3/26 Ionis Pharmaceuticals Inc (NASDAQ: IONS) had its price target lowered by analysts at Cantor Fitzgerald from $65.00 to $56.00. They now have a "neutral" rating on the stock. 6.4%
4/8 Ionis establishes $25,000 scholarship to help ALS patients in greater San Diego area participate in physical and mental wellness programs 4.9%
7/17 Form 4 IONIS PHARMACEUTICALS For: Jul 15 Filed by: McDevitt Damien 4.5%
9/10 Ionis Pharmaceuticals Inc (NASDAQ: IONS) was upgraded by analysts at Sanford C. Bernstein from a "market perform" rating to an "outperform" rating. 4.4%
4/23 Ionis Pharmaceuticals Inc (NASDAQ: IONS) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 4.2%
2/16 Ionis Pharmaceuticals Looks Undervalued - Q4, FY Earnings Will Be Important [Seeking Alpha] 3.6%
9/10 Ionis Pharmaceuticals, Inc. (IONS) Presents at 17th Annual Morgan Stanley Global Healthcare Conference (Transcript) [Seeking Alpha] 3.2%
8/7 Q2/2019 6/30/2019 EPS -0.010 ZacksConsensus -0.270 ActVsEst 0.260 - Beat 3.2%
3/3 Form 4 IONIS PHARMACEUTICALS For: Feb 29 Filed by: O'NEIL PATRICK R. 7.6%
3/26 Ionis Pharmaceuticals Inc (NASDAQ: IONS) had its price target lowered by analysts at Cantor Fitzgerald from $65.00 to $56.00. They now have a "neutral" rating on the stock. 6.4%
4/8 Ionis establishes $25,000 scholarship to help ALS patients in greater San Diego area participate in physical and mental wellness programs 4.9%
7/17 Form 4 IONIS PHARMACEUTICALS For: Jul 15 Filed by: McDevitt Damien 4.5%
9/10 Ionis Pharmaceuticals Inc (NASDAQ: IONS) was upgraded by analysts at Sanford C. Bernstein from a "market perform" rating to an "outperform" rating. 4.4%
4/23 Ionis Pharmaceuticals Inc (NASDAQ: IONS) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 4.2%
2/16 Ionis Pharmaceuticals Looks Undervalued - Q4, FY Earnings Will Be Important [Seeking Alpha] 3.6%
9/10 Ionis Pharmaceuticals, Inc. (IONS) Presents at 17th Annual Morgan Stanley Global Healthcare Conference (Transcript) [Seeking Alpha] 3.2%
8/7 Q2/2019 6/30/2019 EPS -0.010 ZacksConsensus -0.270 ActVsEst 0.260 - Beat 3.2%
TOP News Decliners
3/15
Researchers Behind Spinraza Win Breakthrough Prize [Forbes]
-9.9%
7/22 Biogen Earnings: Here's What Investors Are Hoping To See In Report [Investor's Business Daily] -8.8%
3/10 Ionis Pharmaceuticals Inc (NASDAQ: IONS) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -7.0%
10/16 Ionis Pharmaceuticals Inc (NASDAQ: IONS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -6.6%
3/20 Ionis Pharmaceuticals Inc (NASDAQ: IONS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $49.00 price target on the stock. -5.4%
2/26 Ionis Pharmaceuticals' (IONS) CEO Brett Monia on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -4.9%
6/6 Ionis Pharmaceuticals to provide corporate update and 30-year retrospective at its 2019 Annual Meeting of Stockholders -4.7%
9/30 Form 8-K IONIS PHARMACEUTICALS For: Sep 27 -4.6%
2/28 Ionis Pharmaceuticals Inc (NASDAQ: IONS) was upgraded by analysts at TheStreet from a "c" rating to a "b-" rating. -4.2%
12/16 Positive results reaffirm plans to advance ATL1102 for DMD to Phase IIb trial -3.8%
7/22 Biogen Earnings: Here's What Investors Are Hoping To See In Report [Investor's Business Daily] -8.8%
3/10 Ionis Pharmaceuticals Inc (NASDAQ: IONS) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -7.0%
10/16 Ionis Pharmaceuticals Inc (NASDAQ: IONS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -6.6%
3/20 Ionis Pharmaceuticals Inc (NASDAQ: IONS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $49.00 price target on the stock. -5.4%
2/26 Ionis Pharmaceuticals' (IONS) CEO Brett Monia on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -4.9%
6/6 Ionis Pharmaceuticals to provide corporate update and 30-year retrospective at its 2019 Annual Meeting of Stockholders -4.7%
9/30 Form 8-K IONIS PHARMACEUTICALS For: Sep 27 -4.6%
2/28 Ionis Pharmaceuticals Inc (NASDAQ: IONS) was upgraded by analysts at TheStreet from a "c" rating to a "b-" rating. -4.2%
12/16 Positive results reaffirm plans to advance ATL1102 for DMD to Phase IIb trial -3.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: